Search Articles — Sudonull

https://sudonull.com/electric-car-sales-in-europe-up-40-byd-and-tesla-lead

Analysis of EV sales in Europe in April 2026: BYD up 114.5%, Tesla up 46.5%. Why Tesla is losing the ecosystem war and what awaits the market. Read details.

https://sudonull.com/tpms-signals-car-tracking-without-gps

Learn how open dTPMS transmissions reveal routes, type and driving style. Experiment with SDR: 6 million packets, privacy threats. Analysis methods for developers.

https://sudonull.com/intoxalock-cyberattack-car-lockout-in-the-usa

Intoxalock Cyberattack Paralyzed Breathalyzers in 45 States. Details of Failures, IoT Vulnerabilities, and Protection Recommendations. Study Risks for Automotive Systems.

https://sudonull.com/launching-mcu-tesla-model-3-on-the-bench-cables-and-network

How to assemble and run Tesla Model 3 autopilot computer from used parts. Power connection, Rosenberger cables, access to SSH/ODIN. Instructions for reverse engineers.

https://sudonull.com/hybrid-nissan-terrano-phev-2026-concept-for-russia

Nissan presented the Terrano PHEV and Urban SUV plug-in hybrid concepts at the Beijing Auto Show. Learn about the design, power, and release timelines for the production SUVs.

https://ymaho.com/dual-action-car-t-100-remission-in-myeloma-at-isct-2026

ISCT 2026 data analysis: CAR-T therapy TPST-2003 showed complete response in all naive patients. Learn why this is a breakthrough, not an illusion, and what risks are hidden.

https://ymaho.com/car-t-therapy-hiv-years-of-remission-after-infusion

DUET-2 data: CAR-T cells keep HIV in remission for over 2 years without ART. Functional cure already a reality? Learn about the breakthrough in HIV treatment.

https://ymaho.com/car-t-therapy-for-ovarian-cancer-lira-cel-and-28-months-of-life

Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.

https://ymaho.com/next-generation-car-t-tumor-neurobiology-and-brain-cancer-treatment

Scientists propose considering neurotransmitters for CAR-T cells in glioblastoma. A new approach to brain cancer therapy. Learn more.

https://ymaho.com/car-nk-therapy-ab-201-for-esophageal-cancer-efficacy-analysis

Expert analysis of CAR-NK therapy AB-201 for HER2-positive gastric and esophageal cancer. Why this is not a breakthrough? Risks, data, and prospects. Read.

https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026

Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.

https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases

FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.

https://ymaho.com/car-t-therapy-against-aging-elimination-of-senescent-cells

An international consortium has developed CAR-T for selective elimination of senescent cells. Learn how uPAR CAR-T technology fights age-related diseases and fibrosis.

https://ymaho.com/car-t-therapy-for-lupus-100-remission-in-a-small-cohort

German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.

https://ymaho.com/lymphoma-metabolism-new-vulnerabilities-for-car-t-therapy

Nature reveals metabolic subtypes of DLBCL. Learn how glycolysis and lipid inhibitors enhance CAR-T efficacy. Read market forecast until 2028.